Datapoint: Court Ruling Shores Up Eliquis Exclusivity Until 2028

The U.S. Court of Appeals for the Federal Circuit on Sept. 3 upheld a lower court decision that maintains Bristol Myers Squibb and Pfizer’s U.S. exclusivity for their blockbuster heart drug Eliquis until 2028. The ruling is still subject to appeal, however. Eliquis is one of the top-selling drugs in the U.S., and currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. 82.3% of all covered lives have unrestricted preferred access to Eliquis.

SOURCE: MMIT Analytics, as of 9/8/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 17

Datapoint: Clover Health to Settle Shareholder Lawsuits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 16

Datapoint: Michigan Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 15

Datapoint: UCare Partners With Violet to Train Providers in Cultural Competency

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today